LT3682B - Method for preparing amino acid derivatives and pharmaceuthical compositions thereof - Google Patents

Method for preparing amino acid derivatives and pharmaceuthical compositions thereof Download PDF

Info

Publication number
LT3682B
LT3682B LTIP862A LTIP862A LT3682B LT 3682 B LT3682 B LT 3682B LT IP862 A LTIP862 A LT IP862A LT IP862 A LTIP862 A LT IP862A LT 3682 B LT3682 B LT 3682B
Authority
LT
Lithuania
Prior art keywords
formula
compound
acid
hydroxy
isoquinoline
Prior art date
Application number
LTIP862A
Other languages
English (en)
Lithuanian (lt)
Inventor
Joseph Armstrong Martin
Sally Redshaw
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of LTIP862A publication Critical patent/LTIP862A/xx
Publication of LT3682B publication Critical patent/LT3682B/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)
  • Measurement Of Force In General (AREA)
  • Confectionery (AREA)
  • Cleaning Or Clearing Of The Surface Of Open Water (AREA)
LTIP862A 1989-12-11 1993-08-16 Method for preparing amino acid derivatives and pharmaceuthical compositions thereof LT3682B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898927913A GB8927913D0 (en) 1989-12-11 1989-12-11 Amino acid derivatives
SG120493A SG120493G (en) 1989-12-11 1993-11-02 N-tert-Butyl-decahydro-2(3-amino-2-hydroxy-4-phenyl-butyl) isoquinoline-3-carboxamide and asparaginyl derivatives thereof

Publications (2)

Publication Number Publication Date
LTIP862A LTIP862A (en) 1995-03-27
LT3682B true LT3682B (en) 1996-01-25

Family

ID=26296345

Family Applications (1)

Application Number Title Priority Date Filing Date
LTIP862A LT3682B (en) 1989-12-11 1993-08-16 Method for preparing amino acid derivatives and pharmaceuthical compositions thereof

Country Status (48)

Country Link
US (1) US5196438A (fr)
EP (1) EP0432695B1 (fr)
JP (1) JP2807093B2 (fr)
KR (1) KR970005912B1 (fr)
CN (2) CN1034805C (fr)
AT (1) ATE122661T1 (fr)
AU (1) AU634319B2 (fr)
BG (1) BG51452A3 (fr)
BR (1) BR9006264A (fr)
CA (1) CA2030433C (fr)
CU (1) CU22305A3 (fr)
CZ (1) CZ280558B6 (fr)
DE (2) DE69019481T2 (fr)
DK (1) DK0432695T3 (fr)
DZ (1) DZ1467A1 (fr)
EG (1) EG19722A (fr)
ES (1) ES2072959T3 (fr)
FI (2) FI100883B (fr)
GB (2) GB8927913D0 (fr)
GR (1) GR3017114T3 (fr)
HK (1) HK129093A (fr)
HR (1) HRP930341B1 (fr)
HU (2) HU207298B (fr)
ID (1) ID1018B (fr)
IE (1) IE67523B1 (fr)
IL (1) IL96550A (fr)
IN (1) IN172553B (fr)
IS (1) IS1803B (fr)
LT (1) LT3682B (fr)
LU (1) LU90014I2 (fr)
LV (1) LV5738B4 (fr)
MA (1) MA22014A1 (fr)
MC (1) MC2195A1 (fr)
MT (1) MTP1075B (fr)
MW (1) MW8890A1 (fr)
MX (1) MX173630B (fr)
NL (1) NL970013I2 (fr)
NO (1) NO176566C (fr)
OA (1) OA09334A (fr)
PL (1) PL165225B1 (fr)
PT (1) PT96145B (fr)
RO (1) RO107942B1 (fr)
RU (1) RU2071470C1 (fr)
SG (1) SG120493G (fr)
SI (1) SI9012315B (fr)
SK (1) SK280249B6 (fr)
ZA (1) ZA909743B (fr)
ZW (1) ZW17490A1 (fr)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878728B1 (en) 1999-06-11 2005-04-12 Vertex Pharmaceutical Incorporated Inhibitors of aspartyl protease
US20040122000A1 (en) * 1981-01-07 2004-06-24 Vertex Pharmaceuticals Incorporated. Inhibitors of aspartyl protease
US5614533A (en) * 1987-03-13 1997-03-25 Bio-Mega/Boehringer Ingelheim Research, Inc. Substituted pipecolinic acid derivatives as HIV protease inhibitors
USH1649H (en) 1987-07-31 1997-05-06 Barrish; Joel C. HIV protease inhibitor combinations
CA1340588C (fr) * 1988-06-13 1999-06-08 Balraj Krishan Handa Derive d'aminoacides
GB8927915D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Novel alcohols
US5430041A (en) * 1991-05-10 1995-07-04 Hoffmann-La Roche Inc. Amino acid derivatives having antiviral activity
US5508407A (en) * 1991-07-10 1996-04-16 Eli Lilly And Company Retroviral protease inhibitors
CN1071930A (zh) * 1991-07-10 1993-05-12 伊莱利利公司 用作治疗艾滋病的人免疫缺陷病毒蛋白酶的抑制剂
WO1993008184A1 (fr) * 1991-10-23 1993-04-29 Merck & Co., Inc. Inhibiteurs de la protease du vih______________________
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
CA2081970C (fr) * 1991-11-08 1997-07-08 Joseph P. Vacca Utilisation d'agents inhibant la protease du vih pour le traitement du sida
US5888992A (en) 1992-03-11 1999-03-30 Narhex Limited Polar substituted hydrocarbons
JPH07504654A (ja) 1992-03-11 1995-05-25 ナルヘックス　リミテッド オキソ及びヒドロキシ置換炭化水素のアミン誘導体
US6071895A (en) 1992-03-11 2000-06-06 Narhex Limited Polar-substituted hydrocarbons
EP0560268B1 (fr) * 1992-03-13 1995-01-04 Bio-Mega/Boehringer Ingelheim Research Inc. Dérivés de l'acide pipécolinic comme inhibiteurs de HIV-protéase
EP0957093A3 (fr) * 1992-05-21 2000-04-12 Monsanto Company Inhibiteurs de protéase rétrovirales
US5559256A (en) * 1992-07-20 1996-09-24 E. R. Squibb & Sons, Inc. Aminediol protease inhibitors
DK0810209T3 (da) 1992-08-25 2002-08-12 Monsanto Co Alpha - and beta-aminosyre-hydroxyethylaminosulfonamider til anvendelse som inhibitorer af retrovirale proteaser
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
US5783701A (en) 1992-09-08 1998-07-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
TW372972B (en) * 1992-10-23 1999-11-01 Novartis Ag Antiretroviral acyl compounds
US5380849A (en) * 1992-11-09 1995-01-10 Merck & Co., Inc. Process for optically pure decahydroisoqiunolines
US5430150A (en) * 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors
US5491166A (en) * 1992-12-22 1996-02-13 Eli Lilly And Company Inhibitors of HIV protease useful for the treatment of AIDS
MX9308025A (es) * 1992-12-22 1994-08-31 Lilly Co Eli Compuestos inhibidores de la proteasa del virus dela inmunodeficiencia humana, procedimiento para supreparacion y formulacion farmaceutica que los contiene.
US5846993A (en) * 1992-12-22 1998-12-08 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5733906A (en) * 1993-10-12 1998-03-31 Eli Lilly And Company Inhibitors of HIV Protease useful for the treatment of Aids
US5434265A (en) * 1992-12-22 1995-07-18 Eli Lilly And Company Inhibitors of HIV protease
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
MX9308016A (es) * 1992-12-22 1994-08-31 Lilly Co Eli Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.
US5693815A (en) * 1993-01-17 1997-12-02 Schering Corporation Peptides
US5939430A (en) * 1993-02-22 1999-08-17 Merrell Pharmaceuticals Inc. Combinations of retroviral inhibitors
US5455353A (en) * 1993-03-24 1995-10-03 Hoffmann-La Roche Inc. 4-(benzyl-2-oxo-oxazolidin-5 ylmethyl)N tertbutyl-decahydroisoquinoline-3-carboxamides
EP0738724B1 (fr) * 1993-07-15 1998-11-04 F. Hoffmann-La Roche Ag Procédé de préparation d'un dérivé N-terbutylamide
DE69426655T2 (de) * 1994-02-02 2001-06-13 Eli Lilly And Co., Indianapolis Hiv-protease inhibitoren und zwischenprodukte
DE69512220T2 (de) * 1994-03-07 2000-03-16 Vertex Pharmaceuticals Inc. Sulfonamidderivate als aspartylprotease-inhibitoren
US5527829A (en) * 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5470979A (en) * 1994-07-01 1995-11-28 American Cyanamid Company Asymmetric synthesis of bicyclic amino acid esters
US5523463A (en) * 1994-09-23 1996-06-04 Hoffmann-La Roche Inc. Method of producing halogenated and alpha-aminoalchohols
US5591885A (en) * 1994-09-23 1997-01-07 Hoffman-La Roche Inc. Process for the preparation of halogenated α-aminoketone compounds
US5691372A (en) * 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
US6008228A (en) * 1995-06-06 1999-12-28 Hoffman-La Roche Inc. Pharmaceutical compositions containing proteinase inhibitors
CZ292192B6 (cs) * 1995-06-06 2003-08-13 F. Hoffmann-La Roche Ag Jednotková dávka farmaceutického prostředku, který je inhibitorem proteinázy
US6004957A (en) * 1995-06-07 1999-12-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
AU759386B2 (en) * 1995-06-29 2003-04-10 Abbvie Inc. Use of Ritonavir (ABT-538) for improving the pharmacokinetics of drugs metabolized by cytochrome P450 in a method of treating AIDS
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
ES2246498T3 (es) 1995-11-13 2006-02-16 Vitaleech Bioscience N.V. Aislados antivirales obtenidos de sanguijuelas.
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5883252A (en) * 1996-01-26 1999-03-16 Vertex Pharmaceuticals Incorporated Aspartyl protease inhibitors
US5587481A (en) * 1996-02-20 1996-12-24 The Monsanto Company Preparation of (S)-decahydroisoquinoline-3-carboxylic acid t-butylamide
EP0823424A1 (fr) * 1996-08-09 1998-02-11 F. Hoffmann-La Roche Ag Procédé pour la préparation de quinargine
US5914404A (en) * 1996-08-09 1999-06-22 Hoffmann-La Roche Inc. Process for the preparation of quinargine
US5925759A (en) 1996-09-05 1999-07-20 Agouron Pharmaceuticals, Inc. Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors
US5962725A (en) 1996-09-05 1999-10-05 Agouron Pharmaceuticals, Inc. Intermediate compounds useful for making HIV protease inhibitors such as nelfinavir
US5705647A (en) * 1996-09-05 1998-01-06 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
US6232333B1 (en) * 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
ATE236880T1 (de) 1996-12-11 2003-04-15 Hoffmann La Roche Verfahren zur herstellung gemischter anhydride
US6001851A (en) * 1997-03-13 1999-12-14 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US6084107A (en) * 1997-09-05 2000-07-04 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
US6143742A (en) * 1997-12-11 2000-11-07 Fuisz Technologies Ltd Treatment for necrotizing infections
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
FR2779653B1 (fr) * 1998-06-11 2002-12-20 Inst Nat Sante Rech Med Utilisation de composes modulateurs du proteasome en therapie
AU767728B2 (en) 1998-06-19 2003-11-20 Vertex Pharmaceuticals Incorporated Sulfonamide inhibitors of aspartyl protease
US6509468B1 (en) * 1998-10-21 2003-01-21 Fujisawa Pharmaceutical Co., Ltd. Vitreous form of known bradykinin antagonist
KR100277723B1 (ko) 1998-12-14 2001-01-15 남창우 광학적으로 순수한 데카하이드로이소퀴놀린카르복사미드의 연속제조공정
US7635690B2 (en) * 1999-01-22 2009-12-22 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
US7115584B2 (en) * 1999-01-22 2006-10-03 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
US6765019B1 (en) 1999-05-06 2004-07-20 University Of Kentucky Research Foundation Permeable, water soluble, non-irritating prodrugs of chemotherapeutic agents with oxaalkanoic acids
DK1733725T4 (da) * 1999-06-04 2012-09-17 Abbott Lab Farmaceutiske formuleringer omfattende mindst én HIV-proteaseinhiberende forbindelse
US6589962B1 (en) 1999-07-20 2003-07-08 Merck & Co., Inc. Alpha-hydroxy-gamma-[[(carbocyclic-or heterocyclic-substituted)amino]carbonyl]alkanamide derivatives and uses thereof
WO2001005230A1 (fr) * 1999-07-20 2001-01-25 Merck & Co., Inc. Derives alpha-hydroxy-gamma-[[(carbocycliques-ou heterocycliques-substitues)amino]carbonyle]alcanamide et utilisations de ceux-ci
AU777824B2 (en) 1999-11-24 2004-11-04 Merck Sharp & Dohme Corp. Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1- piperazinepentanamides as HIV protease inhibitors
IT1313682B1 (it) * 1999-11-25 2002-09-09 Archimica Spa Procedimento per la preparazione di (s)-n-terbutil-1,2,3,4-tetraidroisochinolin-3-carbossiammide.
BR0011864A (pt) 2000-01-19 2004-07-20 Abbott Lab Formulações farmacêuticas
AU2001259817A1 (en) * 2000-05-04 2001-11-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The National Institutes Of Health Methods of and compounds for inhibiting calpains
IT1318986B1 (it) * 2000-10-09 2003-09-19 Archimica S P A Ora Clariant L Procedimento per la preparazione di (s)-n-terbutil-1,2,3,4-tetraidroisochinolin-3-carbossiammide.
GB0028483D0 (en) 2000-11-22 2001-01-10 Hoffmann La Roche Hydroxyethylamine HIV protease inhibitors
US20030191121A1 (en) * 2001-08-09 2003-10-09 Miller Ross A. Piperazine carboxamide intermediates of HIV protease inhibitors and processes for their preparation
AU2002359721A1 (en) 2001-12-19 2003-07-09 Bristol-Myers Squibb Company Pichia pastoris formate dehydrogenase and uses therefor
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
US20040067216A1 (en) * 2002-02-22 2004-04-08 Karki Shyam B. Hiv protease inhibitors supported on cation exchange resins for oral administration
US7157489B2 (en) * 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
US7115652B2 (en) * 2002-06-17 2006-10-03 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
EP1515944A1 (fr) * 2002-06-17 2005-03-23 Sunesis Pharmaceuticals, Inc. Inhibiteurs de l'aspartyl-protease
NZ544585A (en) * 2003-07-11 2008-04-30 Hoffmann La Roche Saquinavir mesylate oral dosage form
EP1604662A1 (fr) * 2004-06-08 2005-12-14 Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft Derivés de la benzyl amine du acide carboxylique (2R) de la 1-[(3R)-Amino-4-(2-fluoro-phenyl)-butyl]-pyrrolidine et composés similaires pour l'utilisation comme inhibiteurs de la peptidase dipeptidyl IV (DPP-IV) pour le traitement de la diabetes mellitus de type 2
PL216369B1 (pl) 2004-07-27 2014-03-31 Gilead Sciences Pochodne fosfonianowe, kompozycje farmaceutyczne zawierające te pochodne oraz zastosowanie tych pochodnych do wytwarzania leku do hamowania wirusa HIV
WO2006134612A1 (fr) * 2005-06-16 2006-12-21 Hetero Drugs Limited Procédé de préparation du saquinavir à l’aide d’un nouvel intermédiaire
WO2008112289A2 (fr) 2007-03-12 2008-09-18 Nektar Therapeutics Conjugués d'oligomère-inhibiteur de protéase
NZ582086A (en) * 2007-06-29 2012-07-27 Gilead Sciences Inc Therapeutic compositions and the use thereof
CN101743004A (zh) * 2007-06-29 2010-06-16 吉里德科学公司 治疗用组合物及其用途
CA2700132A1 (fr) * 2007-09-25 2009-04-02 Merck Sharp & Dohme Corp. Inhibiteurs de la protease du vih
WO2009114151A1 (fr) * 2008-03-12 2009-09-17 Nektar Therapeutics Conjugués oligomères-acides aminés et oligomères-atazanavir
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
WO2010077613A1 (fr) 2008-12-09 2010-07-08 Gilead Sciences, Inc. Modulateurs de récepteurs de type toll (tlr)
EP2376515A1 (fr) 2008-12-23 2011-10-19 Pharmasset, Inc. Synthèse de nucléosides de type purine
US8551973B2 (en) * 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
CA2748057C (fr) * 2008-12-23 2018-07-03 Pharmasset, Inc. Phosphoramidates de nucleosides
CA2762582A1 (fr) 2009-05-27 2010-12-02 Merck Sharp & Dohme Corp. Inhibiteurs de la protease du vih
JP2012530069A (ja) 2009-06-12 2012-11-29 ネクター セラピューティックス プロテアーゼ阻害剤、水溶性非ペプチドオリゴマーおよび親油性部分を含む共有結合体
DE102010004957A1 (de) 2010-01-14 2011-07-21 Universitätsklinikum Jena, 07743 Biologisch wirksame Moleküle zur Beeinflussung von Virus-, Bakterien-, Parasiten-infizierten Zellen und/oder Tumorzellen und Verfahren zu deren Anwendung
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
CL2011000718A1 (es) 2010-03-31 2012-04-09 Gilead Pharmasset Llc Proceso para la preparacion de compuestos fosforados enantiomericos.
EP2632895B1 (fr) 2010-10-28 2018-10-03 Merck Canada Inc. Inhibiteurs de la protéase du vih
EP2392926A1 (fr) 2011-02-09 2011-12-07 Roche Diagnostics GmbH Biomarqueurs urinaires chez des sujets infectés par le VIH
EP2771332B1 (fr) 2011-10-26 2016-06-29 Merck Canada Inc. Dérivés sulfonamides de thiophen et thiazol en tant qu'inhibiteurs de la protease du HIV pour le traitement du SIDA
WO2013105118A1 (fr) 2012-01-10 2013-07-18 Council Of Scientific & Industrial Research Procédé pour la synthèse d' azido-époxyde synthétique et son utilisation en tant qu'intermédiaire de la synthèse d'amprénavir et de saquinavir
RU2015113091A (ru) 2012-09-11 2016-11-10 Мерк Шарп И Доум Корп. Ингибиторы протеазы вич
WO2014068265A1 (fr) 2012-10-29 2014-05-08 Cipla Limited Analogues de phosphonate antiviraux et leur procédé de préparation
WO2015013835A1 (fr) 2013-07-31 2015-02-05 Merck Sharp & Dohme Corp. Dérivés de pipérazine utilisés en tant qu'inhibiteurs de la protéase du vih
US9737545B2 (en) 2013-12-19 2017-08-22 Merck Sharp & Dohme Corp. HIV protease inhibitors
US9834526B2 (en) 2013-12-19 2017-12-05 Merck Sharp & Dohme Corp. HIV protease inhibitors
EP3113780B1 (fr) 2014-03-06 2019-08-14 Merck Sharp & Dohme Corp. Inhibiteurs de la protéase du vih
WO2015138220A1 (fr) 2014-03-10 2015-09-17 Merck Sharp & Dohme Corp. Dérivés de pipérazine utilisés en tant qu'inhibiteurs de la protéase du vih
WO2016001907A1 (fr) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv et mogroside v utilisables en tant qu'agonistes/stimulateurs/agents de déblocage des récepteurs toll 4 et adjuvant destiné à être utilisé dans un vaccin humain/animal et pour stimuler l'immunité contre des agents pathologiques
EP4140485A1 (fr) 2014-07-11 2023-03-01 Gilead Sciences, Inc. Modulateurs de récepteurs de type toll pour le traitement du vih
US9738664B2 (en) 2014-10-29 2017-08-22 Wisconsin Alumni Research Foundation Boronic acid inhibitors of HIV protease
HK1257270A1 (zh) 2015-09-15 2019-10-18 Gilead Sciences, Inc. 用於治療hiv的toll樣受體(tlr)調節劑
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0346847A2 (fr) 1988-06-13 1989-12-20 F. Hoffmann-La Roche Ag Dérivés d'amminoacides

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB933968A (en) * 1960-10-26 1963-08-14 May & Baker Ltd New phthalimide derivatives
US4123543A (en) * 1971-09-16 1978-10-31 Ab Kabi Derivatives of substituted indoline lactans with effect on the central nervous system
US3901897A (en) * 1972-10-05 1975-08-26 Squibb & Sons Inc 1,2,3,4,4a,5,6,7-octahydro-7-aryl-isoquinolines and derivatives thereof
US4329473A (en) * 1979-06-01 1982-05-11 Almquist Ronald G Oxoalkanoic acid derivatives as inhibitors of angiotensin converting enzyme
SE421551B (sv) * 1980-03-26 1982-01-04 Sandvik Ab Borrverktyg for rotations- och/eller slagborrning
US4470973A (en) * 1982-07-19 1984-09-11 E. R. Squibb & Sons, Inc. Substituted peptide compounds
US4812442A (en) * 1984-05-29 1989-03-14 Merck & Co., Inc. Tripeptide renin inhibitors
FR2575753B1 (fr) * 1985-01-07 1987-02-20 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AT383762B (de) * 1985-12-23 1987-08-25 Plansee Metallwerk Verfahren zur herstellung mehrkomponentiger, kongruent erschmelzender lotmaterialien
CA1286989C (fr) * 1985-12-26 1991-07-30 A. Arthur Gottlieb Immunoamplificateurs et composes apparentes
WO1988000939A1 (fr) * 1986-07-25 1988-02-11 Banyu Pharmaceutical Co., Ltd. Derives d'amino-alcools optiquement actifs et procede pour leur preparation
DE3789347D1 (de) * 1986-10-14 1994-04-21 Banyu Pharma Co Ltd 5-Substituierte Amino-4-hydroxy-pentansäure-Derivate und deren Verwendung.
US4863905A (en) * 1987-02-04 1989-09-05 Warner-Lambert Company Renin inhibitors II
FR2610934B1 (fr) * 1987-02-13 1989-05-05 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE3717631A1 (de) * 1987-05-26 1988-12-15 Merck Patent Gmbh Aminosaeurederivate
DE3733296A1 (de) * 1987-10-02 1989-04-20 Merck Patent Gmbh Aminosaeurederivate
IL89900A0 (en) * 1988-04-12 1989-12-15 Merck & Co Inc Hiv protease inhibitors useful for the treatment of aids and pharmaceutical compositions containing them
DE4033062A1 (de) * 1990-10-18 1992-04-23 Merck Patent Gmbh Aminosaeurederivate
GB8927915D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Novel alcohols

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0346847A2 (fr) 1988-06-13 1989-12-20 F. Hoffmann-La Roche Ag Dérivés d'amminoacides

Also Published As

Publication number Publication date
SK576590A3 (en) 1999-10-08
GB2239016A (en) 1991-06-19
CN1052482A (zh) 1991-06-26
DE69019481D1 (de) 1995-06-22
GB9026776D0 (en) 1991-01-30
NL970013I2 (nl) 1997-09-01
AU634319B2 (en) 1993-02-18
GB8927913D0 (en) 1990-02-14
IL96550A0 (en) 1991-09-16
FI100883B (fi) 1998-03-13
CZ280558B6 (cs) 1996-02-14
PL165225B1 (pl) 1994-11-30
CA2030433A1 (fr) 1991-06-12
EP0432695B1 (fr) 1995-05-17
ATE122661T1 (de) 1995-06-15
PL288201A1 (en) 1991-09-09
IL96550A (en) 1995-03-15
HU211342A9 (en) 1995-11-28
SI9012315B (sl) 1998-06-30
NO905322D0 (no) 1990-12-10
RU2071470C1 (ru) 1997-01-10
LV5738B4 (lv) 1996-12-20
JPH03255076A (ja) 1991-11-13
SG120493G (en) 1994-01-21
EG19722A (en) 1996-01-31
CA2030433C (fr) 1997-10-21
DZ1467A1 (fr) 2004-09-13
DE69019481T2 (de) 1995-11-09
AU6787690A (en) 1991-06-13
MW8890A1 (en) 1991-03-13
IE904453A1 (en) 1991-06-19
ZW17490A1 (en) 1992-06-17
HUT56073A (en) 1991-07-29
KR970005912B1 (en) 1997-04-22
SI9012315A (en) 1997-10-31
MC2195A1 (fr) 1992-10-05
RO107942B1 (ro) 1994-01-31
PT96145A (pt) 1991-09-30
FI905983L (fi) 1991-06-12
BR9006264A (pt) 1991-09-24
MX23619A (es) 1993-10-01
EP0432695A2 (fr) 1991-06-19
GB2239016B (en) 1993-08-04
DK0432695T3 (da) 1995-09-11
HRP930341B1 (en) 1998-12-31
KR910011894A (ko) 1991-08-07
FI905983A0 (fi) 1990-12-04
FI973895A7 (fi) 1997-10-06
GR3017114T3 (en) 1995-11-30
MA22014A1 (fr) 1991-07-01
DE19675051I2 (de) 2001-04-12
ZA909743B (en) 1991-08-28
ES2072959T3 (es) 1995-08-01
CN1138983A (zh) 1997-01-01
SK280249B6 (sk) 1999-10-08
OA09334A (fr) 1992-09-15
IN172553B (fr) 1993-09-25
MX173630B (es) 1994-03-18
HU908076D0 (en) 1991-06-28
IS3651A7 (is) 1991-06-12
US5196438A (en) 1993-03-23
ID1018B (id) 1996-10-18
EP0432695A3 (en) 1991-12-18
BG51452A3 (bg) 1993-05-14
IS1803B (is) 2002-02-26
HRP930341A2 (en) 1994-10-31
IE67523B1 (en) 1996-04-03
LU90014I2 (fr) 1997-01-31
JP2807093B2 (ja) 1998-09-30
FI973895A0 (fi) 1997-10-06
FI973895L (fi) 1997-10-06
HU207298B (en) 1993-03-29
CN1066329C (zh) 2001-05-30
CZ576590A3 (en) 1995-11-15
PT96145B (pt) 1998-04-30
LTIP862A (en) 1995-03-27
NO176566C (no) 1995-04-26
NO905322L (no) 1991-06-12
HK129093A (en) 1993-12-03
LV5738A4 (lv) 1996-08-20
NL970013I1 (nl) 1997-05-01
MTP1075B (en) 1991-07-31
CU22305A3 (es) 1995-01-31
CN1034805C (zh) 1997-05-07
NO176566B (no) 1995-01-16

Similar Documents

Publication Publication Date Title
LT3682B (en) Method for preparing amino acid derivatives and pharmaceuthical compositions thereof
US4294832A (en) Tetrahydroisoquinoline compounds and a pharmaceutical composition thereof
JP2515019B2 (ja) アミノ酸誘導体
AU606901B2 (en) Novel phosphinic acid derivatives
EP0643072B1 (fr) Composés dérivés de la 2-piperazinone et leur emploi
RU2232760C2 (ru) Ингибитор сериновых протеаз и фармацевтическая композиция на его основе
DE60221508T2 (de) Aminosäurederivate als hiv-protease-inhibitoren
KR20000016700A (ko) 뎁시 펩티드 및 이를 유효 성분으로 하는 의약
US4216209A (en) Tripeptide angiotensin converting enzyme inhibitors
US4587250A (en) Thiazaspirane derivatives, process for their preparation, and medicaments
KR870001239B1 (ko) 테트라하이드로-β-카르보린 유도체의 제조방법
FR2594831A1 (fr) Derives de proline, leur procede de preparation, composition pharmaceutique en comportant et procede d'inhibition de l'enzyme transformant l'angiotensine
JPH07126286A (ja) 新規なペプチド誘導体
BG60367B2 (bg) Аминокиселинни производни
JPH075633B2 (ja) アミノ酸誘導体その製造方法及び血圧降下剤
RU2109731C1 (ru) Производные аминокислоты и их фармацевтически приемлемые соли, которые являются основными, способы получения производных аминокислоты и фармацевтическая композиция, обладающая антивирусной активностью
SA90110168B1 (ar) مشتقات الاحماض الامينية.
JPH07157472A (ja) ２−ピペラジノン−１−酢酸誘導体およびその用途

Legal Events

Date Code Title Description
SPCF Filing an spc

Free format text: PRODUCT NAME: (S)-N-((ALFAS)-ALFA-((1R)-2-((3S,4AS,8AS)-3-(TRET-BUTILKARBAMOIL)OKTAHIDRO-2(1H)-IZOCHINOLIL)-1-HIDROKSIETIL)-2-CHINALDAMIDO SUKCINAMIDAS, MEZILATAS (SAQUINAVIR); REGISTRATION NO/DATE: EU/1/96/026/001 19961004

Spc suppl protection certif: PA2004003

Filing date: 20040730

Expiry date: 20130816

SPCR Rejection of an spc

Free format text: PRODUCT NAME: (S)-N-((ALFAS)-ALFA-((1R)-2-((3S,4AS,8AS)-3-(TRET-BUTILKARBAMOIL)OKTAHIDRO-2(1H)-IZOCHINOLIL)-1-HIDROKSIETIL)-2-CHINALDAMIDO SUKCINAMIDAS, MEZILATAS (SAQUINAVIR); REGISTRATION NO/DATE: EU/1/96/026/001 19961004

Spc suppl protection certif: PA2004003

Filing date: 20040730

Expiry date: 20130816

Effective date: 20050927

MK9A Expiry of a patent

Effective date: 20130816